ANI Pharmaceuticals counsel sells 500 ANIP shares

ANI Pharmaceuticals senior vice president and general counsel Meredith Cook reported a small open-market sale of 500 shares of common stock at $72.62 per share.

Rhea-AI Filing Summary

ANI Pharmaceuticals senior vice president and general counsel Meredith Cook reported a small open-market sale of 500 shares of common stock at $72.62 per share. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 15, 2025.

After this sale, Cook still directly owns 79,390 shares, so the trade represents a minor portion of her overall reported holdings and appears to be a routine, pre-planned liquidity event rather than a major change in ownership.

Insider Trade Summary 10b5-1

Net Seller: 500 shares

Net Sell 1 txn

Insider Cook Meredith

Role SR. VP, GENERAL COUNSEL & SEC.

Sold 500 shs ($36K)

Type	Security	Shares	Price	Value
Sale	Common Stock	500	$72.62	$36K

Holdings After Transaction: Common Stock — 79,390 shares (Direct)

Footnotes (1)

1. F1. The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did ANI Pharmaceuticals (ANIP) report for Meredith Cook?

ANI Pharmaceuticals reported that senior vice president and general counsel Meredith Cook sold 500 shares of common stock. The shares were sold in an open-market transaction at $72.62 per share, and the trade was disclosed on a Form 4 insider filing.

At what price did Meredith Cook sell ANI Pharmaceuticals (ANIP) shares?

Meredith Cook sold ANI Pharmaceuticals common stock at $72.62 per share. The Form 4 describes this as an open-market sale of 500 shares, providing investors with both the transaction size and the executed price for this specific insider trade.

How many ANI Pharmaceuticals (ANIP) shares does Meredith Cook hold after the sale?

Following the reported sale, Meredith Cook directly holds 79,390 shares of ANI Pharmaceuticals common stock. This indicates the 500 shares sold represent a small fraction of her total reported holdings, suggesting the transaction is limited relative to her remaining position.

Was the ANI Pharmaceuticals (ANIP) insider sale made under a Rule 10b5-1 plan?

Yes. The footnotes state the sale was effected under a Rule 10b5-1 trading plan adopted on September 15, 2025. Such plans allow insiders to pre-schedule trades, helping separate routine portfolio management from discretionary market-timing decisions.

What type of transaction code appears on Meredith Cook’s ANI Pharmaceuticals (ANIP) Form 4?

The Form 4 lists transaction code "S," indicating a sale in the open market or private transaction. The filing classifies this as a non-derivative transaction in common stock, with 500 shares sold and no associated option exercises or derivative conversions.

Does the Meredith Cook Form 4 for ANI Pharmaceuticals (ANIP) involve derivatives or options?

No. The filing shows a single non-derivative transaction in common stock and a derivative section with no remaining derivative positions reported. There are no option exercises, conversions, or other derivative transactions disclosed in this particular Form 4.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/13/2026 - 05:28 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cook Meredith

(Last) (First) (Middle)

C/O ANI PHARMACEUTICALS, INC.

210 MAIN STREET WEST

(Street)

BAUDETTE MN 56623

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ANI PHARMACEUTICALS INC [ ANIP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SR. VP, GENERAL COUNSEL & SEC.

3. Date of Earliest Transaction (Month/Day/Year)
03/13/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/13/2026		S(1)		500	D	$72.62	79,390	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025.

Remarks:

	/s/ Meredith W. Cook	03/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.